Global RLT Therapy Market Strategic Research Report

Scope of the Report

The global RLT Therapy market size is predicted to grow from US$ 3,131 million in 2025 to US$ 6,409 million in 2032; it is expected to grow at a CAGR of 10.7% from 2026 to 2032.

Radioligand therapy is an advanced targeted cancer treatment method. Its core principle involves precisely delivering a cell-killing radionuclide to the lesion via a precisely designed "biological missile"—a ligand molecule that specifically recognizes markers on the surface of tumor cells. This design achieves cellular-level precision delivery, similar to internal radiation therapy: the radionuclide releases high-energy rays locally on the tumor, destroying the DNA of cancer cells while maximally protecting surrounding healthy tissue due to its extremely short radiation range. This therapy typically follows a "therapeutic approach," first using paired drugs with conjugated diagnostic radionuclides to perform imaging examinations to screen suitable patients and assess target expression levels, thus achieving truly personalized precision medicine.

Radioligand therapy shows great promise, evolving from a specialty therapy targeting a few specific targets into one of the core pillars of oncology. Its growth is driven by multiple factors: First, the range of targets is constantly expanding, moving from mature targets like PSMA and SSTR to new targets such as FAP and CDH6, covering a wider range of solid tumors beyond prostate cancer and neuroendocrine tumors. Second, radionuclide innovation is accelerating, with alpha radionuclide therapy becoming a research hotspot due to its stronger killing power and precision, and holding promise for treating more advanced or drug-resistant patients. In the future, "integrated diagnosis and treatment" will become the standard paradigm, driving precise pre-treatment screening and real-time monitoring of efficacy.

This report presents a comprehensive overview of the global RLT Therapy market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Types of Radiation

• Beta Particle Therapy
• Alpha Particle Therapy
• Auger Electron Therapy

Segment by Primary Targets

• PSMA
• SSTR
• Others

Segment by Treatment Strategies

• Integrated Therapy
• Standalone Treatment

Segment by players, this report covers

• Novartis
• Lilly
• Telix Pharmaceuticals
• ITM Isotope Technologies Munich
• Curium Pharma
• Bristol Myers Squibb
• AstraZeneca
• POINT Biopharma
• Orano Med
• RadioMedix

Segment by Application

• Prostate Cancer Related
• Neuroendocrine Tumors

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global RLT Therapy market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Prostate Cancer Related, Neuroendocrine Tumors evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact